Cardiology Today

Welcome to Cardiology Today – Recorded September 05, 2025. This episode summarizes 2 key cardiology studies on topics like Clinical Trials and Protein Phosphatase 5. Key takeaway: Arachidonic Acid Drives Post-Infarct Inflammation. Article Links: Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. (European heart journal) Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/arachidonic-acid-drives-post-infarct-inflammation-09-05-25/ Featured Articles Article 1: Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905492 Summary: This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction. Article 2: Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40905476 Summary: This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. Transcript Today’s date is September 05, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction. This study found that arachidonic acid, a polyunsaturated fatty acid metabolite, plays a critical role in driving post myocardial infarction inflammation by activating macrophage protein phosphatase 5. Single cell RNA sequencing revealed cardiac macrophage heterogeneity after myocardial infarction in mice and metabolomic analysis profiled polyunsaturated fatty acid metabolites in both mice and human patients. These findings suggest that targeting the arachidonic acid metabolic cascade could offer a novel therapeutic approach to modulate inflammation and improve cardiac repair after myocardial infarction. Article number two. Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions. This article discusses the challenges and potential solutions for using decline in glomerular filtration rate as an endpoint in Heart Failure clinical trials, highlighting the interconnectedness of chronic kidney disease and cardiovascular disease. It addresses the importance of understanding how to best assess chronic kidney disease progression in the context of Heart Failure, given the increasing evidence for common therapies in both disease states and the cardiorenal metabolic syndrome framework. The piece is a review and perspective offering guidance for clinicians and regulatory agencies. Thank you for listening. Don’t forget to subscribe. Keywords Clinical Trials, Protein Phosphatase 5, Arachidonic Acid, Heart Failure, Macrophages, Myocardial Infarction, Cardiorenal Metabolic Syndrome, Inflammation, Chronic Kidney Disease, Glomerular Filtration Rate. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Arachidonic Acid Drives Post-Infarct Inflammation 09/05/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 04, 2025. This episode summarizes 5 key cardiology studies on topics like gestational hypertension and Mendelian randomization. Key takeaway: Clonal Hematopoiesis Links to CAD Mortality. Article Links: Article 1: Clinical care of family members of patients with dilated cardiomyopathy. (European heart journal) Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. (European heart journal) Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. (European heart journal) Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. (European heart journal) Article 5: Sexual minority populations and disparities in cardiovascular healthcare. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/clonal-hematopoiesis-links-to-cad-mortality-09-04-25/ Featured Articles Article 1: Clinical care of family members of patients with dilated cardiomyopathy. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40902100 Summary: This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies. Article 2: Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900121 Summary: This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies. Article 3: Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900118 Summary: This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis. Article 4: Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900105 Summary: This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease. Article 5: Sexual minority populations and disparities in cardiovascular healthcare. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40900101 Summary: This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system. Transcript Today’s date is September 04, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Clinical care of family members of patients with dilated cardiomyopathy. This consensus statement emphasizes tailoring cardiac screening regimens for family members of individuals with dilated cardiomyopathy based on both genetic and clinical information. It highlights the importance of genetic family screening after identifying a pathogenic variant in a proband, and recommends cardiac screening for all first-degree relatives. The approach advocates for individualized risk assessment at both individual and familial levels to optimize screening strategies. Article number two. Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study. This genetic epidemiology study used Mendelian randomization to investigate the causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease risk. Analyzing data from FinnGen and other consortia, the study aimed to determine if the observed associations between preeclampsia, gestational hypertension and cardiovascular outcomes reflect true causal pathways. These results could inform targeted prevention strategies for women with a history of hypertensive pregnancies. Article number three. Sex-specific outcomes after transcatheter or surgical treatment of aortic valve stenosis: the DEDICATE-DZHK6 trial. This analysis of the DEDICATE-DZHK6 trial examines sex-specific outcomes in patients with aortic stenosis undergoing transcatheter aortic valve implantation or surgical aortic valve replacement. While the main trial demonstrated non-inferiority of transcatheter aortic valve implantation compared to surgery, this pre-defined descriptive analysis focuses on differences in outcomes between men and women. Understanding these sex-specific nuances can help refine treatment strategies for aortic stenosis. Article number four. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. This study investigated the link between clonal haematopoiesis of indeterminate potential and all-cause mortality in patients with angiographically confirmed coronary artery disease. Through deep sequencing of genes associated with clonal haematopoiesis of indeterminate potential in over 8,600 patients, the research identifies the prognostic relevance and explores the mechanisms by which clonal haematopoiesis of indeterminate potential, particularly TET2 mutations, impacts mortality in coronary artery disease. The findings may refine risk stratification and treatment strategies in patients with coronary artery disease. Article number five. Sexual minority populations and disparities in cardiovascular healthcare. This review highlights the increased risk of cardiovascular disease among sexual minority populations compared to heterosexual individuals, emphasizing the influence of minority stressors on cardiovascular health. It discusses the minority stress model, which posits that stressors across multiple levels contribute to cardiovascular disease risk in lesbian, gay, bisexual, queer, and other non-heterosexual people. Addressing these disparities requires understanding and mitigating minority stressors within the healthcare system. Thank you for listening. Don’t forget to subscribe. Keywords gestational hypertension, Mendelian randomization, clonal haematopoiesis of indeterminate potential, dilated cardiomyopathy, preeclampsia, gay, queer, genetic screening, TET2 mutations, bisexual, surgical aortic valve replacement, family screening, aortic stenosis, transcatheter aortic valve implantation, sex-specific outcomes, genetic epidemiology, sexual minority, DEDICATE-DZHK6 trial, cardiovascular disease, coronary artery disease, pathogenic variants, health disparities, all-cause mortality, lesbian, cardiac risk, cardiovascular risk, minority stress. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Clonal Hematopoiesis Links to CAD Mortality 09/04/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 1 key cardiology studies on topics like adipose tissue and obesity. Key takeaway: Obesity’s Unclear Role in Heart Failure with Reduced Ejection. Article Links: Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/obesitys-unclear-role-in-heart-failure-with-reduced-ejection-09-03-25/ Featured Articles Article 1: Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40891153 Summary: The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. Transcript Today’s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction? This article discusses the unclear role of obesity and visceral adiposity in the development of Heart Failure with Reduced Ejection Fraction, contrasting it with their established role in Heart Failure with Preserved Ejection Fraction. The abstract highlights that while central adiposity is common in Heart Failure with Preserved Ejection Fraction patients, obesity was not a prominent feature in older Heart Failure with Reduced Ejection Fraction trials. The study investigates whether expanded adipose tissue mass significantly contributes to the progression of Heart Failure with Reduced Ejection Fraction. Thank you for listening. Don’t forget to subscribe. Keywords adipose tissue, obesity, Heart Failure with Reduced Ejection Fraction, visceral adiposity, Heart Failure with Preserved Ejection Fraction. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Obesity’s Unclear Role in Heart Failure with Reduced Ejection 09/03/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 03, 2025. This episode summarizes 5 key cardiology studies on topics like comorbidities and cardiomyocytes. Key takeaway: Lipoprotein(a) Predicts Vascular Disease Risk. Article Links: Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. (Circulation) Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. (Circulation) Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. (Circulation) Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. (Circulation) Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-predicts-vascular-disease-risk-09-03-25/ Featured Articles Article 1: Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40785542 Summary: This prospective study within the Nurses’ Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor. Article 2: Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40718930 Summary: This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease. Article 3: PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40665909 Summary: This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia. Article 4: Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40631661 Summary: This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease. Article 5: Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892534 Summary: This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction. Transcript Today’s date is September 03, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Experiences of Stalking and Obtaining a Restraining Order Are Associated With Onset of Cardiovascular Events in Women: A Prospective Analysis in the Nurses’ Health Study II. This prospective study within the Nurses’ Health Study II found that women who experienced stalking, particularly those who obtained restraining orders, had a significantly higher risk of developing cardiovascular events. The increased risk highlights the long-term cardiovascular consequences of interpersonal violence and the potential need for targeted screening and intervention in women with a history of stalking. These findings underscore the importance of addressing violence as a cardiovascular risk factor. Article number two. Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. This study evaluated lipoprotein a as a marker for extracoronary atherosclerotic vascular disease progression. Results indicated that elevated lipoprotein a levels are associated with a higher risk of developing extracoronary atherosclerotic vascular disease and related complications, suggesting it may serve as a useful prognostic biomarker. These results reinforce the need for considering lipoprotein a levels in risk assessment for atherosclerotic vascular disease. Article number three. PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations. This research investigated the role of PIEZO1 in hereditary hemorrhagic telangiectasia arteriovenous malformations. The study found that PIEZO1 is overexpressed in arteriovenous malformations associated with hereditary hemorrhagic telangiectasia, particularly those caused by activin receptor-like kinase 1 mutations. This suggests a potential therapeutic target for managing arteriovenous malformations in hereditary hemorrhagic telangiectasia. Article number four. Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. This study identified PHF7 as a potent epigenetic factor that enhances the direct reprogramming of fibroblasts into cardiomyocytes in vitro. In a model of myocardial infarction, PHF7-mediated reprogramming improved cardiac function. These findings suggest PHF7 could be a key factor in developing cell-based therapies for ischemic heart disease. Article number five. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. This review article discusses the mechanisms and treatment of left ventricular hypertrophy and myocardial fibrosis in Heart Failure with Preserved Ejection Fraction. It highlights the role of comorbidities like hypertension, obesity, and diabetes in promoting adverse cardiac remodeling and fibrosis. The review emphasizes the need for targeted therapies addressing these underlying comorbidities to improve outcomes in Heart Failure with Preserved Ejection Fraction. Thank you for listening. Don’t forget to subscribe. Keywords comorbidities, cardiomyocytes, cardiac remodeling, interpersonal violence, cellular reprogramming, cardiovascular events, hereditary hemorrhagic telangiectasia, Heart Failure with Preserved Ejection Fraction, left ventricular hypertrophy, extracoronary disease, restraining order, stalking, myocardial infarction, prognosis, myocardial fibrosis, PHF7, PIEZO1, vascular endothelial growth factor receptor 2, atherosclerotic vascular disease, women’s health, biomarker, lipoprotein(a), arteriovenous malformations, activin receptor-like kinase 1, fibroblasts. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Lipoprotein(a) Predicts Vascular Disease Risk 09/03/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like coronary flow capacity and cardiovascular events. Key takeaway: AI Spots Vulnerable Plaques, Predicts MI Risk. Article Links: Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. (Journal of the American College of Cardiology) Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. (European heart journal) Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. (European heart journal) Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. (European heart journal) Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/ai-spots-vulnerable-plaques-predicts-mi-risk-09-02-25/ Featured Articles Article 1: Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40866049 Summary: This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease. Article 2: Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40569854 Summary: This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies. Article 3: Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40439159 Summary: The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures. Article 4: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888677 Summary: The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease. Article 5: Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888584 Summary: The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population. Transcript Today’s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease: Results From MINDS-ACHD. This prospective study examined neurocognitive dysfunction in adults with moderate to severe complex congenital heart disease. The study found a significant prevalence of neurocognitive deficits in this population, and identified risk factors such as atrial fibrillation, heart failure and repeated cardiac interventions that contribute to cognitive impairment. These findings highlight the need for routine neurocognitive screening and targeted interventions to improve long-term outcomes in adults with congenital heart disease. Article number two. Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study. This large, nationwide study from Sweden evaluated the association between adverse pregnancy outcomes and long-term stroke risk. Results demonstrated that women with a history of preterm delivery or who were small for gestational age experienced a significantly elevated long-term risk of stroke. These findings underscore the importance of considering adverse pregnancy outcomes as a risk factor for later-life cardiovascular disease and stroke prevention strategies. Article number three. Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. The CENTURY trial investigated whether an intensive medical management strategy guided by coronary flow capacity assessment via positron emission tomography (PET) could improve outcomes in patients with stable chronic coronary artery disease compared to standard care. The study demonstrated that this comprehensive approach, using revascularization only for those with severely reduced coronary flow capacity, led to improvements in risk factors. It also reduced the need for subsequent revascularization procedures. Article number four. Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study. The PECTUS-AI study evaluated the use of artificial intelligence to identify thin-cap fibroatheromas, a high-risk plaque feature, using optical coherence tomography images in patients after myocardial infarction. The study found that the artificial intelligence algorithm accurately identified thin-cap fibroatheromas and was predictive of future adverse cardiovascular events. This suggests that artificial intelligence can improve risk stratification and potentially guide targeted interventions in patients with coronary artery disease. Article number five. Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial. The OPINION trial investigated the efficacy of surgical left atrial appendage occlusion in patients undergoing valvular surgery who did not have atrial fibrillation but had a CHA₂DS₂-VASc score of 2 or greater. The study did not demonstrate a significant reduction in postoperative thromboembolic events with surgical left atrial appendage occlusion compared to no occlusion. Therefore, prophylactic surgical left atrial appendage occlusion cannot be recommended for stroke prevention in this patient population. Thank you for listening. Don’t forget to subscribe. Keywords coronary flow capacity, cardiovascular events, heart failure, artificial intelligence, preterm delivery, atrial fibrillation, stroke prevention, optical coherence tomography, myocardial infarction, medical management, cardiovascular risk, small for gestational age, surgical left atrial appendage occlusion, valvular heart disease, thin-cap fibroatheroma, adverse pregnancy outcomes, myocardial revascularization, cardiac interventions, stroke, positron emission tomography, neurocognitive dysfunction, congenital heart disease, thromboembolic events, chronic coronary artery disease. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post AI Spots Vulnerable Plaques, Predicts MI Risk 09/02/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 02, 2025. This episode summarizes 5 key cardiology studies on topics like hospitalization and older adults. Key takeaway: Aficamten Superior to Metoprolol in HCM?. Article Links: Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. (The New England journal of medicine) Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. (The New England journal of medicine) Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine) Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. (The New England journal of medicine) Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/aficamten-superior-to-metoprolol-in-hcm-09-02-25/ Featured Articles Article 1: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888716 Summary: This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction. Article 2: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888702 Summary: This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies. Article 3: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888697 Summary: This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy. Article 4: RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888695 Summary: This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine’s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population. Article 5: High-Dose Influenza Vaccine to Reduce Hospitalizations. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888694 Summary: This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group. Transcript Today’s date is September 02, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. This open-label randomized trial in Denmark and Norway found no significant difference in the composite outcome of death from any cause, new myocardial infarction, or hospitalization for heart failure between patients with a left ventricular ejection fraction of 40 percent or greater who received long-term beta-blocker therapy and those who did not after myocardial infarction. Specifically, the study challenges the routine use of beta-blockers in this patient population in the era of modern reperfusion and secondary prevention. The findings suggest a need to re-evaluate guidelines regarding long-term beta-blocker use post myocardial infarction in patients without heart failure or reduced ejection fraction. Article number two. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. This open-label randomized trial in Spain and Italy evaluated beta-blocker therapy versus no beta-blocker therapy in acute myocardial infarction patients with or without ST-segment elevation, but without reduced ejection fraction. The study found no significant difference in the primary composite outcome of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, or major bleeding at a median of 3.5 years, suggesting that routine beta-blocker use in this contemporary setting may not provide additional benefit. This calls into question current guideline recommendations that are based on older trials before routine reperfusion and complete revascularization strategies. Article number three. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. This international, double-blind, randomized trial compared aficamten monotherapy to metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. The study concluded that aficamten led to a statistically significantly greater reduction from baseline in the Valsalva left ventricular outflow tract gradient at week 12 compared to metoprolol; aficamten also resulted in a greater proportion of patients achieving an improvement of at least one New York Heart Association functional class. These findings suggest aficamten may be a more effective monotherapy option than metoprolol for managing symptomatic obstructive hypertrophic cardiomyopathy. Article number four. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. This pragmatic, open-label trial evaluated the Respiratory Syncytial Virus prefusion F protein-based vaccine in adults 60 years or older. The study found that the vaccine did not significantly reduce the risk of hospitalization for Respiratory Syncytial Virus-related lower respiratory tract disease, though there was a trend towards lower hospitalization rates. The researchers suggest further research is warranted to assess the vaccine’s effectiveness in preventing more severe Respiratory Syncytial Virus outcomes in this population. Article number five. High-Dose Influenza Vaccine to Reduce Hospitalizations. This registry-based, open-label trial evaluated the effectiveness of high-dose inactivated influenza vaccine versus standard-dose vaccine in adults 65 years or older. Results showed no significant reduction in hospitalizations for influenza or pneumonia with the high-dose vaccine compared to the standard-dose vaccine. This suggests that, despite prior evidence of superior protection against laboratory-confirmed influenza, the high-dose vaccine does not significantly reduce hospitalizations in this age group. Thank you for listening. Don’t forget to subscribe. Keywords hospitalization, older adults, mortality, metoprolol, secondary prevention, beta-blockers, Respiratory Syncytial Virus, Respiratory Syncytial Virus vaccine, influenza vaccine, myocardial infarction, respiratory illness, aficamten, all-cause mortality, cardiac myosin inhibitors, revascularization, pneumonia, left ventricular outflow tract gradient, left ventricular ejection fraction, high-dose vaccine, ejection fraction, hypertrophic cardiomyopathy. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Aficamten Superior to Metoprolol in HCM? 09/02/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results. Article Links: Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. (The New England journal of medicine) Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. (The New England journal of medicine) Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. (The New England journal of medicine) Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. (The New England journal of medicine) Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/ Featured Articles Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888739 Summary: This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk. Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888734 Summary: This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population. Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888730 Summary: This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation. Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888720 Summary: This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly. Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888717 Summary: This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk. Article number two. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population. Article number three. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation. Article number four. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly. Article number five. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications. Thank you for listening. Don’t forget to subscribe. Keywords Olezarsen, influenza vaccine, resistant hypertension, nonobstructive Hypertrophic Cardiomyopathy, systolic blood pressure, cardiovascular risk, hospitalization, provoking factors, aldosterone synthase inhibitor, high-dose vaccine, apixaban, functional capacity, anticoagulation, recurrent thrombosis, hypertension, cardiac myosin, antisense oligonucleotide, Hypertrophic Cardiomyopathy, venous thromboembolism, older adults, baxdrostat, vaccine effectiveness, mavacamten, apolipoprotein C-III, hypertriglyceridemia. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like stent implantation and community health workers. Key takeaway: Aspirin: Is It Safe to Stop It Early?. Article Links: Article 1: Home-Based Care for Hypertension in Rural South Africa. (The New England journal of medicine) Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. (The New England journal of medicine) Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. (The New England journal of medicine) Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. (The New England journal of medicine) Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/aspirin-is-it-safe-to-stop-it-early-09-01-25/ Featured Articles Article 1: Home-Based Care for Hypertension in Rural South Africa. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888742 Summary: This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations. Article 2: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888737 Summary: This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome. Article 3: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888726 Summary: This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention. Article 4: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888725 Summary: This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants. Article 5: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888723 Summary: This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Home-Based Care for Hypertension in Rural South Africa. This open-label trial in South Africa investigated a home-based hypertension care model involving patient blood pressure monitoring, community health worker home visits for data collection and medication delivery, and remote nurse-led decision making. The intervention significantly improved blood pressure control compared to usual care, demonstrating the effectiveness of community-based strategies in managing hypertension in resource-limited settings. This approach holds promise for expanding access to and improving hypertension management in similar populations. Article number two. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. This registry-based clinical trial assessed whether adding ticagrelor to aspirin, compared with aspirin alone, reduces cardiovascular events after coronary-artery bypass grafting for acute coronary syndrome. The study found no significant difference in the composite outcome of all-cause mortality, myocardial infarction, stroke, or repeat revascularization between the ticagrelor-aspirin and aspirin-only groups at one year. Therefore, aspirin monotherapy appears sufficient for most patients following coronary artery bypass grafting post acute coronary syndrome. Article number three. Early Discontinuation of Aspirin after Percutaneous Coronary Intervention in Low-Risk Acute Myocardial Infarction. This multicenter trial examined early aspirin discontinuation after percutaneous coronary intervention in acute myocardial infarction patients deemed low-risk. Patients who discontinued aspirin after one week and continued P2Y12 inhibitor monotherapy had similar rates of major adverse cardiovascular events compared to those receiving twelve months of dual antiplatelet therapy. This suggests that early aspirin withdrawal may be a safe strategy in select low-risk acute myocardial infarction patients undergoing percutaneous coronary intervention. Article number four. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. This randomized, placebo-controlled trial evaluated the role of aspirin in chronic coronary syndrome patients on long-term oral anticoagulation after previous stent implantation. The addition of aspirin to oral anticoagulation did not significantly reduce the risk of thrombotic events but did significantly increase the risk of major bleeding. These findings support the strategy of avoiding aspirin in chronic coronary syndrome patients already receiving oral anticoagulants. Article number five. Early Withdrawal of Aspirin after Percutaneous Coronary Intervention in Acute Coronary Syndromes. This study investigated whether P2Y12 inhibitor monotherapy without aspirin, initiated shortly after successful percutaneous coronary intervention, is effective and safe for patients with acute coronary syndromes. Early aspirin withdrawal and P2Y12 inhibitor monotherapy, compared to standard dual antiplatelet therapy, resulted in similar rates of the primary composite outcome of death, myocardial infarction, stroke, or major bleeding. Thus, early aspirin cessation with P2Y12 inhibitor monotherapy appears non-inferior to dual antiplatelet therapy in acute coronary syndrome patients post percutaneous coronary intervention. Thank you for listening. Tap ‘more’ for full notes and links. Keywords stent implantation, community health workers, aspirin, home-based care, blood pressure control, rural health, P2Y12 inhibitor, oral anticoagulation, coronary-artery bypass grafting, bleeding risk, hypertension, antiplatelet therapy, drug-eluting stent, ticagrelor, acute coronary syndrome, dual antiplatelet therapy, percutaneous coronary intervention, acute myocardial infarction, acute coronary syndromes, chronic coronary syndrome, aspirin withdrawal. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Aspirin: Is It Safe to Stop It Early? 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like hypokalemia and cardiac wasting. Key takeaway: Low Potassium Linked to Atrial Fibrillation Risk. Article Links: Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. (European heart journal) Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. (European heart journal) Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. (European heart journal) Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. (European heart journal) Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/low-potassium-linked-to-atrial-fibrillation-risk-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219 Summary: This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death. Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211 Summary: Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects. Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202 Summary: This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention. Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168 Summary: This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management. Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884070 Summary: The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated that KCNH2-specific suppression-and-replacement gene therapy, delivered via adeno-associated virus serotype 9, effectively corrected the short QT phenotype in a transgenic rabbit model of type 1 Short QT Syndrome. Specifically, the gene therapy normalized cardiac repolarization and QT intervals, addressing the underlying genetic cause of the arrhythmia. These results suggest a potential therapeutic strategy for Short QT Syndrome using targeted gene therapy to prevent ventricular arrhythmias and sudden cardiac death. Article number two. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Analysis of the REBOOT trial data showed that in post-myocardial infarction patients with left ventricular ejection fraction greater than 40 percent, beta-blocker therapy did not significantly reduce the risk of death or new myocardial infarction in either men or women. Furthermore, women experienced a nominally significant increase in the composite outcome of all-cause death or new myocardial infarction with beta-blocker use, although this was not statistically significant after adjustment. These findings suggest a need for re-evaluation of routine beta-blocker use after myocardial infarction in patients with preserved ejection fraction, with consideration for potential sex-specific effects. Article number three. Hypokalaemia and atrial fibrillation detected by implanted loop recorders. This post hoc analysis of the LOOP study, utilizing data from patients with stroke risk factors and implanted loop recorders, revealed a significant association between low plasma potassium levels and the occurrence of atrial fibrillation. Specifically, each 0.1 millimole per liter decrease in plasma potassium was associated with a 7 percent increased risk of atrial fibrillation detection. These findings highlight the importance of maintaining adequate potassium levels in individuals at risk for atrial fibrillation and suggest that potassium monitoring and management could be a potential strategy for atrial fibrillation prevention. Article number four. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. This study found that elevated circulating levels of imidazole propionate, a metabolite produced by gut microbiota, are associated with increased cardiometabolic risk in patients with coronary artery disease. High imidazole propionate levels were predictive of major adverse cardiovascular events in independent cohorts of patients with acute coronary syndrome. These findings suggest that imidazole propionate may serve as a biomarker for identifying high-risk patients with coronary artery disease and highlight the potential role of gut microbiota modulation in cardiovascular disease prevention and management. Article number five. Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). The EMPATICC trial, studying patients with advanced cancer receiving palliative care, is an ongoing trial designed to evaluate the safety and efficacy of heart failure therapies in this unique patient population. The trial aims to determine if heart failure treatment can improve self-care ability in patients with stage 4 solid tumors and cardiovascular risk factors, who are experiencing a heart failure-like phenotype. Outcomes from this trial will provide insights into managing cardiovascular complications in advanced cancer patients and optimizing their quality of life. Thank you for listening. Tap ‘more’ for full notes and links. Keywords hypokalemia, cardiac wasting, implanted loop recorder, myocardial infarction, KCNH2, cardiometabolic risk, palliative care, sex differences, gut microbiota, ventricular arrhythmias, beta-blockers, imidazole propionate, left ventricular ejection fraction, stroke risk, atrial fibrillation, heart failure, dyspnea, gene therapy, advanced cancer, cardiac repolarization, coronary artery disease, potassium levels, Short QT Syndrome, acute coronary syndrome, REBOOT trial. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Low Potassium Linked to Atrial Fibrillation Risk 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome. Article Links: Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. (European heart journal) Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. (European heart journal) Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. (European heart journal) Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. (European heart journal) Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758 Summary: This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population. Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757 Summary: The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events. Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558 Summary: The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population. Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439 Summary: This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine’s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection. Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413 Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.Article number two. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.Article number three. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.Article number four. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine’s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.Article number five. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords acute coronary syndrome, aspirin resistance, antiplatelet therapy, inclisiran, low-density lipoprotein cholesterol, hypercholesterolemia, vaccine, respiratory syncytial virus, diabetes mellitus, mortality, screening, coronary artery calcification, atherosclerotic cardiovascular disease, respiratory tract infection, respiratory outcomes, cardiovascular disease, influenza vaccine, proprotein convertase subtilisin/kexin type 9, cardiovascular outcomes. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Aspirin Dose Upregulation Fails After Acute Coronary Syndrome 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like antiplatelet therapy and thrombosis. Key takeaway: Lipoprotein(a) Elevates Family Cardiac Risk. Article Links: Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. (European heart journal) Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. (European heart journal) Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. (European heart journal) Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. (European heart journal) Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/lipoproteina-elevates-family-cardiac-risk-09-01-25-2/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161 Summary: This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction. Article 2: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease. Article 3: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063 Summary: This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease. Article 4: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061 Summary: The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells. Article 5: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060 Summary: This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. <p>Article number one. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. This analysis of the GALACTIC-HF trial found that lower serum magnesium concentrations were associated with a higher risk of the primary composite outcome in patients with Heart Failure with Reduced Ejection Fraction. Specifically, each 0.1 milligram per deciliter decrease in magnesium was linked to a statistically significant increase in the risk of heart failure hospitalization or cardiovascular death. This suggests that serum magnesium levels may serve as a prognostic marker in Heart Failure with Reduced Ejection Fraction.</p><p>Article number two. Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. This registry-based study revealed that first-degree relatives of individuals with elevated Lipoprotein(a) levels had a significantly increased risk of major adverse cardiovascular events, including myocardial infarction and ischemic stroke, compared to those without elevated Lipoprotein(a). This elevated risk highlights the familial clustering of cardiovascular disease related to Lipoprotein(a) and underscores the importance of screening family members of individuals with high Lipoprotein(a). The study reinforces Lipoprotein(a) as a causal factor in atherosclerotic cardiovascular disease.</p><p>Article number three. Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. This study characterized reticulated platelets in patients with coronary artery disease, demonstrating their hyperreactive and prothrombotic nature through enhanced signaling pathways and increased interaction with leukocytes. The research identified specific molecular targets within these platelets that could be exploited for novel antiplatelet therapies, potentially improving outcomes in coronary artery disease patients who exhibit suboptimal responses to current treatments. These findings implicate reticulated platelets as key contributors to thrombotic risk in coronary artery disease.</p><p>Article number four. Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. The SEMA-VR CardioLink-15 trial demonstrated that semaglutide treatment in high-risk patients favorably modulates bone marrow-derived progenitor cells, shifting them toward an anti-inflammatory and pro-regenerative profile. Specifically, semaglutide increased the levels of circulating vascular regenerative cells, suggesting a potential mechanism by which glucagon-like peptide-1 receptor agonists reduce major atherosclerotic cardiovascular events. These findings suggest that semaglutide may promote vascular repair and reduce atherothrombotic risk through modulation of vascular progenitor cells.</p><p>Article number five. CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. This study demonstrated that CRISPR activation effectively upregulated the expression of the Filamin C gene in mice carrying a truncating variant known to cause dilated cardiomyopathy, leading to the repair of electrocardiogram abnormalities. This suggests that CRISPR activation could be a promising therapeutic strategy for patients with Filamin C-related cardiomyopathies who currently lack gene-specific treatments. The research highlights the potential of CRISPR technology to address genetic causes of heart disease by enhancing gene expression rather than directly editing the genome.</p> Thank you for listening. Tap ‘more’ for full notes and links. Keywords antiplatelet therapy, thrombosis, CRISPR activation, atherothrombotic risk, prothrombotic signaling, serum magnesium, lipoprotein(a), electrocardiogram abnormalities, glucagon-like peptide-1 receptor agonists, vascular regeneration, filamin C, reticulated platelets, coronary artery disease, dilated cardiomyopathy, semaglutide, myocardial infarction, first-degree relatives, atherosclerotic cardiovascular disease, GALACTIC-HF trial, heart failure with reduced ejection fraction, gene therapy, cardiovascular death, bone marrow-derived progenitor cells, heart failure hospitalization, ischemic stroke. About Concise summaries of cardiovascular research for profe

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective. Article Links: Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation) Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation) Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. (Circulation) Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. (Circulation) Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047 Summary: This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments. Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562 Summary: This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy. Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766 Summary: The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation. Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676 Summary: This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy. Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.Article number two. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.Article number three. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.Article number four. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.Article number five. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords PRADA II trial, breast cancer, microvascular endothelial cells, TAILORED-CHIP trial, antiplatelet therapy, Hypertrophic Cardiomyopathy, CCN2 signaling, genetic architecture, percutaneous coronary intervention, vasculopathy, sarcomere genes, cardiotoxicity, angiotensin receptor neprilysin inhibitor, antiphospholipid syndrome, intermediate effect variants, DOUBLE-CHOICE trial, disease expression, platelet inhibition, sacubitril-valsartan, transfemoral transcatheter aortic valve implantation, transcatheter aortic valve implantation, aortic stenosis, dual antiplatelet therapy, YAP1 signaling, minimalist approach. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post TAVR: Minimalist Approach Proven Safe and Effective 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline. Article Links: Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation) Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation) Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation) Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109 Summary: The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes. Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786 Summary: This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure. Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774 Summary: This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions. Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771 Summary: This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting. Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768 Summary: This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis. <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p><p>Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.</p><p>Article number two. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.</p><p>Article number three. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.</p><p>Article number four. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.</p><p>Article number five. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.</p><p><em>Thank you for listening. Tap ‘more’ for full notes and links.</em></p> </div> Keywords biomarker, mitral regurgitation, ivabradine, mitral valve surgery, noncardiac surgery, valve replacement, stroke, transcatheter aortic valve implantation, MITRACURE registry, bicuspid aortic valve, surgical aortic valve replacement, transcatheter aortic valve replacement, atrial fibrillation, low-risk patients, heart rate control, myocardial injury, randomized controlled trial, aortic stenosis, cerebral embolic protection, valve repair, cognitive function, beta-blockers, stroke prevention, ABC-AF risk score. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Cardiac Glycoside and Artificial Intelligence. Key takeaway: Rehab Improves Outcomes Post-Myocardial Infarction. Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine) Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine) Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-improves-outcomes-post-myocardial-infarction-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction. Article 2: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction. Article 3: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported. Article 4: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population. Article 5: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This international, double-blind, placebo-controlled trial evaluated digitoxin in patients with chronic heart failure who had a left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV or a left ventricular ejection fraction of 30 percent or less and a New York Heart Association functional class of II. The study found no significant difference between digitoxin and placebo in the composite outcome of death from cardiovascular causes or hospitalization for worsening heart failure. These findings do not support the use of digitoxin in patients with heart failure and reduced ejection fraction.Article number two. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial assessed the benefit of multidomain rehabilitation interventions in older patients, specifically those 65 years of age or older with myocardial infarction and impaired physical performance. Patients receiving comprehensive rehabilitation, including cardiovascular risk factor control, dietary counseling, and exercise training, experienced significant improvements in physical performance compared to those receiving usual care. This trial supports the use of multidomain rehabilitation to improve outcomes in older adults following myocardial infarction.Article number three. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. This multicenter, open-label, event-driven, randomized superiority trial investigated whether increasing plasma potassium levels reduces the risk of ventricular arrhythmias in high-risk patients. Participants with an implantable cardioverter-defibrillator were enrolled, and the study found that actively increasing plasma potassium levels to the high-normal range did not reduce the risk of ventricular arrhythmias or all-cause mortality. Therefore, actively increasing potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias is not supported.Article number four. Reduction of Antihypertensive Treatment in Nursing Home Residents. This multicenter, randomized, controlled trial evaluated the effects of reducing antihypertensive treatment in frail, older nursing home residents. The study found that a protocol-driven strategy of progressive reduction of antihypertensive treatment did not significantly reduce the risk of death or cardiovascular events compared to usual care. These results suggest that carefully monitored reduction of antihypertensive medications may be a safe strategy in this population.Article number five. Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. This study assessed the condition-specific performance of artificial intelligence enhanced electrocardiogram models, to detect specific anatomical and functional cardiac abnormalities using data from electronic health records and prospective cohorts. The study demonstrated that artificial intelligence electrocardiogram models can identify distinct cardiovascular phenotypes, but also capture broader cardiovascular risk associations. This suggests artificial intelligence electrocardiogram models have both condition-specific and generalizable risk prediction capabilities. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiac Glycoside, Artificial Intelligence, Phenotypes, Cardiovascular Death, All-Cause Mortality, Physical Performance, Frailty, Rehabilitation, Nursing Home Residents, Ventricular Arrhythmias, Potassium, Myocardial Infarction, Blood Pressure, Risk Prediction, Cardiovascular Risk Factors, Digitoxin, Antihypertensive Treatment, Implantable Cardioverter-Defibrillator, Exercise Training, Heart Failure with Reduced Ejection Fraction, Hospitalization, Electrocardiogram, Cardiovascular Events, Cardiovascular Diagnosis, Hypokalemia. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Rehab Improves Outcomes Post-Myocardial Infarction 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?. Article Links: Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation) Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation) Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation) Article 4: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation) Article 5: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation) <p>Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</p> <h3> Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3> Featured Articles</h3> <h4>Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884774″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884774</a></p> <p><strong>Summary:</strong> This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient’s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.</p> <h4>Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884771″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884771</a></p> <p><strong>Summary:</strong> This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.</p> <h4>Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884768″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884768</a></p> <p><strong>Summary:</strong> The NOTION-2 trial’s three-year follow-up compared tran… (Full details on website)The post Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like mitral valve surgery and frailty. Key takeaway: De-escalating Hypertension in Frail Elderly is Safe. Article Links: Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. (The New England journal of medicine) | Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. (The New England journal of medicine) | Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. (Circulation) | Article 4: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) | Article 5: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/de-escalating-hypertension-in-frail-elderly-is-safe-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879429 Summary: This Danish, multi-center, open-label, randomized trial investigated actively increasing plasma potassium levels in patients at high risk for ventricular arrhythmias who had an implantable cardioverter-defibrillator. The study was stopped early due to slow enrollment and a low number of events, concluding that an active strategy of increasing plasma potassium was not associated with a lower risk of ventricular arrhythmias or death, but did show a potential association with an increased risk of hyperkalemia. This suggests further research is necessary to determine optimal potassium management in this high-risk population. Article 2: Reduction of Antihypertensive Treatment in Nursing Home Residents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879421 Summary: This French, multi-center, randomized, controlled trial examined the effects of reducing antihypertensive medications in nursing home residents aged 80 or older with systolic blood pressure below 130 millimeters of mercury. Results showed that a protocol-driven strategy of progressive antihypertensive treatment reduction did not significantly increase the risk of death or serious adverse events compared to usual care. The study suggests that de-escalation of antihypertensive therapy may be safe in frail, older adults in nursing homes. Article 3: Phenotypic Selectivity of Artificial Intelligence-enhanced Electrocardiography in Cardiovascular Diagnosis and Risk Prediction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888124 Summary: This study investigated the performance of artificial intelligence-enhanced electrocardiogram models to detect specific cardiac conditions versus broad cardio… (Full details on website)The post De-escalating Hypertension in Frail Elderly is Safe 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Risk Factors and Exercise Training. Key takeaway: Rehab After MI: Impact on Older Patients. Article Links: Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/rehab-after-mi-impact-on-older-patients-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Multidomain Rehabilitation for Older Patients with Myocardial Infarction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879431 Summary: This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. This multicenter, randomized trial in Italy investigated a multidomain rehabilitation intervention versus usual care in older patients with impaired physical performance one month after myocardial infarction. The intervention, encompassing cardiovascular risk factor control, dietary counseling, and exercise training, aimed to improve outcomes in this vulnerable population. The study results and conclusions were not provided within the available text, therefore further details are needed to summarize accurately. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiovascular Risk Factors, Exercise Training, Myocardial Infarction, Cardiac Rehabilitation, Geriatric Cardiology. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Rehab After MI: Impact on Older Patients 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Digitoxin Fails in Heart Failure Trial 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., […] The post Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125 first appeared on Cardiology Today.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., […] The post Heart Failure, Potassium, and Mitral Valve Insights 083125 first appeared on Cardiology Today.